Edwards Lifesciences Forecasts Strong Sales and Earnings Growth in 2012

Published
Thursday, February 2, 2012

U.S. THV Launch Fuels Projected 18 to 22 Percent Underlying Sales Growth; Two New Transcatheter Heart Valve Platforms Debuted; Reaffirms Guidance for 2011

NEW YORK, NY, December 09, 2011 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today will provide investors with information on the initiatives expected to result in strong double-digit sales and earnings growth in 2012. During its annual investor conference in New York City, Edwards' management will also discuss the company's strategy for long-term growth, technology pipeline, U.S. transcatheter valve launch and financial goals for 2012.

"We expect 2012 will be a transformational year for Edwards Lifesciences as we deliver new life saving technologies to patients around the world," said Michael A. Mussallem, chairman and CEO. "We are investing aggressively to drive breakthrough innovations in heart valve treatment and to build on our legacy as a trusted partner for managing the critically ill.

Click here to read more